Pediapharm Nabs Health Canada Approval for Bacterial Ear Infection Treatment

Pediapharm received Health Canada's marketing approval for Otixal to treat a bacterial infection of the middle ear in children.

The approval was based on two multicenter, randomized, double-blind Phase III trials, the Otixal treatment arms stopped ear discharge in shorter times than the ciprofloxacin and fluocinolone acetonide alone arms.

Pediapharm intends to launch Otixal in early 2017.